Kyprolis

Active Ingredient(s): Carfilzomib
FDA Approved: * July 20, 2012
Pharm Company: * ONYX PHARMS INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Kyprolis Overview

Carfilzomib (marketed under the trade name Kyprolis, developed by Onyx Pharmaceuticals) is an anti-cancer drug acting as a selective proteasome inhibitor. Chemically, it is a tetrapeptide epoxyketone and an analog of epoxomicin.[2] The U.S. Food and Drug Administration (FDA) approved it on 20 July 2012 for use in patients with multiple myeloma who have received at least two prior therapies, including treatment with bortezomib and an immunomodulatory therapy (such as lenalidomi...

Read more Kyprolis Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Carfilzomib

Recent Kyprolis Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Carfilzomib

Injection: 60mg
Powder: 10mg/vial, 30mg/vial, 60mg/vial
Unknown: Unknown

Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Kyprolis: (3 results)

Sorted by National Drug Code

76075-101 Kyprolis 60 mg/30ml Intravenous Injection, Powder, Lyophilized, for Solution by Onyx Pharmaceuticals, Inc.
76075-102 Kyprolis 30 mg/15ml Intravenous Injection, Powder, Lyophilized, for Solution by Onyx Pharmaceuticals, Inc.
76075-103 Kyprolis 10 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Onyx Pharmaceuticals, Inc.

Other drugs which contain Carfilzomib or a similar ingredient: (1 result)

CARFILZOMIB